Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Breast Cancer Excellence Forum

Breast Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Erika Hamilton, MD, Sarah Cannon Research Institute
Videos
06/20/2024
Erika Hamilton, MD
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the...
06/20/2024
Oncology
Ruta Rao, MD; Seth Wander, MD, PhD; William Gradishar, MD
Roundtables
06/17/2024
Ruta Rao, MD
William Gradishar, MD
Seth Wander, MD, PhD
In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.
In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.
In this video, a panel of...
06/17/2024
Oncology
Ruta Rao, MD; Seth Wander, MD, PhD; William Gradishar, MD
Roundtables
06/17/2024
Ruta Rao, MD
William Gradishar, MD
Seth Wander, MD, PhD
In this video, a panel of experts discuss the sequencing of antibody drug conjugates of patients with HER2-low metastatic breast cancer, including trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan.
In this video, a panel of experts discuss the sequencing of antibody drug conjugates of patients with HER2-low metastatic breast cancer, including trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan.
In this video, a panel of...
06/17/2024
Oncology
Ruta Rao, MD; Seth Wander, MD, PhD; William Gradishar, MD
Roundtables
06/14/2024
Ruta Rao, MD
William Gradishar, MD
Seth Wander, MD, PhD
In this video, a panel of experts discuss the management of patients with HER2-low metastatic breast cancer, sharing data from the DESTINY-Breast06 trial.
In this video, a panel of experts discuss the management of patients with HER2-low metastatic breast cancer, sharing data from the DESTINY-Breast06 trial.
In this video, a panel of...
06/14/2024
Oncology
Kevin Kalinsky, MD, Winship Cancer Institute
Videos
06/13/2024
Kevin Kalinsky, MD
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares...
06/13/2024
Oncology
Rebecca Shatsky, MD, University of California, San Diego
Videos
06/07/2024
Rebecca Shatsky, MD
Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.
Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.
Rebecca Shatsky, MD, shares...
06/07/2024
Oncology
Seth Wander, MD, PhD, Massachusetts General Hospital
Videos
05/08/2024

Featuring Seth Wander, MD, PhD

Featuring Seth Wander, MD, PhD ...
At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.
At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Denise Yardley, MD, Sarah Cannon Research Institute
Videos
05/08/2024

Featuring Denise Yardley, MD

Featuring Denise Yardley, MD
At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.
At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center
Videos
05/08/2024

Featuring Neil Iyengar, MD

Featuring Neil Iyengar, MD
At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.
At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD
Videos
02/22/2024

Featuring Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Featuring Reshma Mahtani, DO; Terry M...
In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
In this video, a panel of...
02/22/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement